SEMA3A (Semaphorin 3A), also known as Semaphorin-3A or Collapsin-3, is a secreted class 3 semaphorin that functions as a potent axonal guidance cue during development and in adult nervous system function. As a 771 amino acid protein with a characteristic sema domain, SEMA3A plays complex roles in neural circuit formation, synaptic plasticity, and has been implicated in multiple neurodegenerative diseases.
Semaphorins were originally identified as axon repellents that cause growth cone collapse, but research has revealed much more nuanced functions. SEMA3A signals through a receptor complex composed of Neuropilin-1 (NRP1) or Neuropilin-2 (NRP2) together with Plexin-A family receptors to exert its biological effects.
¶ Structure and Biochemistry
SEMA3A possesses a complex multidomain structure essential for its function:
- Sema Domain (residues 1-530): The signature semaphorin domain that mediates receptor binding and is conserved across all semaphorin classes
- PSI Domain (Plexin/Semaphorin/Integrin, residues 531-590): Critical for interactions with Plexin receptors
- C-terminal Basic Domain (residues 650-771): Contains heparin-binding motifs that facilitate interaction with cell surface glycosaminoglycans
¶ Molecular Weight and Properties
- Molecular Weight: ~89 kDa (full-length precursor)
- Isoelectric Point: ~8.2 (basic protein)
- Cellular Localization: Secreted protein, can bind to cell surface and extracellular matrix
- Post-translational Modifications: N-glycosylation, proteolytic processing
SEMA3A signals through a heteromeric receptor complex:
| Receptor |
Role |
Expression Pattern |
| Neuropilin-1 (NRP1) |
Primary binding subunit |
Neurons, endothelial cells, astrocytes |
| Neuropilin-2 (NRP2) |
Alternative binding subunit |
Subset of neurons, endothelial cells |
| Plexin-A1 |
Signaling subunit |
Broad CNS expression |
| Plexin-A2 |
Alternative signaling |
Specific neuronal populations |
| Plexin-A4 |
Alternative signaling |
Motor neurons, sensory neurons |
During embryonic development, SEMA3A serves as a chemorepellent that guides axons away from inappropriate targets:
- Corticospinal Tract Development: SEMA3A expression in the ventral spinal cord repels corticospinal axons from inappropriate midline crossing
- Olfactory System: Guides olfactory axon projection to specific glomeruli in the olfactory bulb
- Hippocampal Circuitry: Regulates dentate gyrus axon targeting
- Cortical Neuron Migration: Influences neuronal positioning during cortical development
In the adult nervous system, SEMA3A continues to play important roles in synaptic plasticity[@de wit2016]:
- Dendritic Spine Morphogenesis: SEMA3A signaling regulates the shape and density of dendritic spines
- Synaptic Strength: Modulates synaptic efficacy through NMDA receptor regulation
- Inhibitory Synapse Formation: Controls GABAergic synapse development
- Long-term Potentiation: Influences LTP induction in hippocampal neurons
SEMA3A modulates immune cell migration and function:
- T Cell Migration: Regulates T cell trafficking through lymphoid organs
- Macrophage Polarization: Influences M1/M2 macrophage differentiation
- Dendritic Cell Function: Modulates antigen presentation and migration
SEMA3A has complex and context-dependent roles in Alzheimer's disease pathogenesis:
Elevated SEMA3A in AD Brain:
- Increased SEMA3A expression in AD hippocampus
- Correlates with tau pathology burden
- May represent compensatory neuroprotective response
Mechanisms:
- Drives axonal guidance abnormalities in AD
- Contributes to hippocampal circuit dysfunction
- Modulates amyloid-beta effects on neurons
- Influences neuroinflammation through microglial regulation
Therapeutic Implications:
- SEMA3A signaling modulators being explored
- NRP1 antagonists may reduce pathological signaling
In Parkinson's disease, SEMA3A has been implicated in dopaminergic neuron survival:
Findings:
- Elevated SEMA3A in substantia nigra of PD patients
- Associated with disease severity
- May contribute to dopaminergic axon degeneration
Mechanisms:
- Impedes dopaminergic axon regeneration
- Promotes neuroinflammation
- Disrupts nigrostriatal circuit plasticity
Therapeutic Targeting:
- Neutralizing SEMA3A antibodies in development
- NRP1 blockade to promote regeneration
SEMA3A plays a significant role in ALS pathogenesis:
Dysregulation:
- Markedly elevated SEMA3A in ALS motor cortex and spinal cord
- Upregulated in both familial and sporadic ALS
- Correlates with disease progression markers
Pathogenic Mechanisms:
- Drives motor neuron axonal degeneration
- Promotes excitatory toxicity
- Impairs axonal regeneration capacity
- Induces microglial activation
Therapeutic Approaches:
- SEMA3A-neutralizing antibodies (e.g., anrunersen in clinical trials)
- Small molecule NRP1 antagonists
- Gene therapy approaches to block SEMA3A signaling
SEMA3A is implicated in demyelinating disease:
- Promotes axonal regeneration failure
- Inhibits oligodendrocyte precursor differentiation
- Contributes to failed remyelination
Huntington's Disease:
- Altered SEMA3A expression in striatum
- Contributes to medium spiny neuron dysfunction
Frontotemporal Dementia:
- Dysregulated semaphorin signaling in FTD
- Associated with TDP-43 pathology
| Approach |
Mechanism |
Development Status |
| Neutralizing Antibodies |
Block SEMA3A-NRP1 interaction |
Clinical trials (ALS) |
| NRP1 Antagonists |
Inhibit receptor binding |
Preclinical |
| Small Molecule Inhibitors |
Block downstream signaling |
Preclinical |
| Gene Therapy |
Deliver SEMA3A antagonists |
Research stage |
Several clinical trials are targeting SEMA3A signaling:
- NCT03739940: Anrunersen (anti-SEMA3A antibody) in ALS - Phase 1/2 complete
- Additional trials evaluating NRP1 modulators in development
¶ Challenges and Considerations
- SEMA3A has both protective and pathogenic roles
- Temporal and spatial specificity matters
- NRP1 has multiple ligands beyond SEMA3A
- Blood-brain barrier penetration required for CNS therapies
SEMA3A has potential as a disease biomarker:
- CSF SEMA3A: Elevated in ALS and AD
- Blood SEMA3A: Correlates with disease severity
- Therapeutic Monitoring: May predict treatment response